Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 45


Androgen receptor-modulatory microRNAs provide insight into therapy resistance and therapeutic targets in advanced prostate cancer.

Fletcher CE, Sulpice E, Combe S, Shibakawa A, Leach DA, Hamilton MP, Chrysostomou SL, Sharp A, Welti J, Yuan W, Dart DA, Knight E, Ning J, Francis JC, Kounatidou EE, Gaughan L, Swain A, Lupold SE, de Bono JS, McGuire SE, Gidrol X, Bevan CL.

Oncogene. 2019 Jul;38(28):5700-5724. doi: 10.1038/s41388-019-0823-5. Epub 2019 May 1.


Adding the Team into T1 Translational Research: A Case Study of Multidisciplinary Team Science in the Evaluation of Biomarkers of Prostate Cancer Risk and Prognosis.

Marrone MT, Joshu CE, Peskoe SB, De Marzo AM, Heaphy CM, Lupold SE, Meeker AK, Platz EA.

Clin Chem. 2019 Jan;65(1):189-198. doi: 10.1373/clinchem.2018.293365. Epub 2018 Dec 5.


PDCD4 Is an Androgen-Repressed Tumor Suppressor that Regulates Prostate Cancer Growth and Castration Resistance.

Zennami K, Choi SM, Liao R, Li Y, Dinalankara W, Marchionni L, Rafiqi FH, Kurozumi A, Hatano K, Lupold SE.

Mol Cancer Res. 2019 Feb;17(2):618-627. doi: 10.1158/1541-7786.MCR-18-0837. Epub 2018 Dec 5.


Cell-type specific expression of oncogenic and tumor suppressive microRNAs in the human prostate and prostate cancer.

Kumar B, Rosenberg AZ, Choi SM, Fox-Talbot K, De Marzo AM, Nonn L, Brennen WN, Marchionni L, Halushka MK, Lupold SE.

Sci Rep. 2018 May 8;8(1):7189. doi: 10.1038/s41598-018-25320-z.


Aptamers and apple pies: a mini-review of PSMA aptamers and lessons from Donald S. Coffey.

Lupold SE.

Am J Clin Exp Urol. 2018 Apr 1;6(2):78-86. eCollection 2018. Review.


The orally active pterocarpanquinone LQB-118 exhibits cytotoxicity in prostate cancer cell and tumor models through cellular redox stress.

Martino T, Kudrolli TA, Kumar B, Salviano I, Mencalha A, Coelho MGP, Justo G, Costa PRR, Sabino KCC, Lupold SE.

Prostate. 2018 Feb;78(2):140-151. doi: 10.1002/pros.23455. Epub 2017 Nov 6.


Differential long-term stability of microRNAs and RNU6B snRNA in 12-20 year old archived formalin-fixed paraffin-embedded specimens.

Peskoe SB, Barber JR, Zheng Q, Meeker AK, De Marzo AM, Platz EA, Lupold SE.

BMC Cancer. 2017 Jan 6;17(1):32. doi: 10.1186/s12885-016-3008-4.


Identification of miR-30b-3p and miR-30d-5p as direct regulators of androgen receptor signaling in prostate cancer by complementary functional microRNA library screening.

Kumar B, Khaleghzadegan S, Mears B, Hatano K, Kudrolli TA, Chowdhury WH, Yeater DB, Ewing CM, Luo J, Isaacs WB, Marchionni L, Lupold SE.

Oncotarget. 2016 Nov 8;7(45):72593-72607. doi: 10.18632/oncotarget.12241.


Development and Application of a Novel Model System to Study "Active" and "Passive" Tumor Targeting.

Mukherjee A, Kumar B, Hatano K, Russell LM, Trock BJ, Searson PC, Meeker AK, Pomper MG, Lupold SE.

Mol Cancer Ther. 2016 Oct;15(10):2541-2550. Epub 2016 Aug 2.


MicroRNA expression and function in prostate cancer: a review of current knowledge and opportunities for discovery.

Kumar B, Lupold SE.

Asian J Androl. 2016 Jul-Aug;18(4):559-67. doi: 10.4103/1008-682X.177839. Review.


Characterization of a novel metastatic prostate cancer cell line of LNCaP origin.

Castanares MA, Copeland BT, Chowdhury WH, Liu MM, Rodriguez R, Pomper MG, Lupold SE, Foss CA.

Prostate. 2016 Feb;76(2):215-25. doi: 10.1002/pros.23115. Epub 2015 Oct 26.


Systemic Administration and Targeted Radiosensitization via Chemically Synthetic Aptamer-siRNA Chimeras in Human Tumor Xenografts.

Ni X, Zhang Y, Zennami K, Castanares M, Mukherjee A, Raval RR, Zhou H, DeWeese TL, Lupold SE.

Mol Cancer Ther. 2015 Dec;14(12):2797-804. doi: 10.1158/1535-7163.MCT-15-0291-T. Epub 2015 Oct 5.


A functional screen identifies miRNAs that inhibit DNA repair and sensitize prostate cancer cells to ionizing radiation.

Hatano K, Kumar B, Zhang Y, Coulter JB, Hedayati M, Mears B, Ni X, Kudrolli TA, Chowdhury WH, Rodriguez R, DeWeese TL, Lupold SE.

Nucleic Acids Res. 2015 Apr 30;43(8):4075-86. doi: 10.1093/nar/gkv273. Epub 2015 Apr 6.


Real-time, near-infrared fluorescence imaging with an optimized dye/light source/camera combination for surgical guidance of prostate cancer.

Neuman BP, Eifler JB, Castanares M, Chowdhury WH, Chen Y, Mease RC, Ma R, Mukherjee A, Lupold SE, Pomper MG, Rodriguez R.

Clin Cancer Res. 2015 Feb 15;21(4):771-80. doi: 10.1158/1078-0432.CCR-14-0891. Epub 2014 Dec 12.


Investigation of miR-21, miR-141, and miR-221 expression levels in prostate adenocarcinoma for associated risk of recurrence after radical prostatectomy.

Zheng Q, Peskoe SB, Ribas J, Rafiqi F, Kudrolli T, Meeker AK, De Marzo AM, Platz EA, Lupold SE.

Prostate. 2014 Dec;74(16):1655-62. doi: 10.1002/pros.22883. Epub 2014 Sep 22.


A novel approach for detecting viable and tissue-specific circulating tumor cells through an adenovirus-based reporter vector.

Wu P, Sokoll LJ, Kudrolli TA, Chowdhury WH, Ma R, Liu MM, Rodriguez R, Lupold SE.

Prostate. 2014 Sep;74(13):1286-1296. doi: 10.1002/pros.22845. Epub 2014 Jul 25.


Evaluation of prostate-specific membrane antigen as an imaging reporter.

Castanares MA, Mukherjee A, Chowdhury WH, Liu M, Chen Y, Mease RC, Wang Y, Rodriguez R, Lupold SE, Pomper MG.

J Nucl Med. 2014 May;55(5):805-11. doi: 10.2967/jnumed.113.134031. Epub 2014 Apr 3.


Correlation of Sprouty1 and Jagged1 with aggressive prostate cancer cells with different sensitivities to androgen deprivation.

Terada N, Shiraishi T, Zeng Y, Aw-Yong KM, Mooney SM, Liu Z, Takahashi S, Luo J, Lupold SE, Kulkarni P, Getzenberg RH.

J Cell Biochem. 2014 Sep;115(9):1505-15. doi: 10.1002/jcb.24805.


Development and screening of a series of antibody-conjugated and silica-coated iron oxide nanoparticles for targeting the prostate-specific membrane antigen.

Mukherjee A, Darlington T, Baldwin R, Holz C, Olson S, Kulkarni P, DeWeese TL, Getzenberg RH, Ivkov R, Lupold SE.

ChemMedChem. 2014 Jul;9(7):1356-60. doi: 10.1002/cmdc.201300549. Epub 2014 Mar 3.


Monitoring nanoparticle-mediated cellular hyperthermia with a high-sensitivity biosensor.

Mukherjee A, Castanares M, Hedayati M, Wabler M, Trock B, Kulkarni P, Rodriguez R, Getzenberg RH, DeWeese TL, Ivkov R, Lupold SE.

Nanomedicine (Lond). 2014 Dec;9(18):2729-43. doi: 10.2217/nnm.13.207.

Supplemental Content

Loading ...
Support Center